Page 2 - தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் Today - Breaking & Trending Today

Sartorius Stedim Biotech acquires cell culture specialist Xell AG

Sartorius Stedim Biotech acquires cell culture specialist Xell AG
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Provence Alpes Côd Azur , Petra Kirchhoff , Stefan Northoff , Head Of Corporate Communications Investor Relations , Sartorius Group , Sartorius Stedim Biotech , Sartorius Stedim Biotech Board , Stedim Biotech , North America , Corporate Communications , ஒன்றுபட்டது மாநிலங்களில் , பெட்ரா கர்க்‌ஹாஃப் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , சர்த்தொறிூச் குழு , வடக்கு அமெரிக்கா , பெருநிறுவன தகவல்தொடர்புகள் ,

Sartorius Stedim Biotech acqui - GuruFocus.com

Sartorius Stedim Biotech acqui - GuruFocus.com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.

United States , Provence Alpes Côd Azur , Petra Kirchhoff , Stefan Northoff , Head Of Corporate Communications Investor Relations , Sartorius Group , Sartorius Stedim Biotech , Sartorius Stedim Biotech Board , Stedim Biotech , North America , Corporate Communications , ஒன்றுபட்டது மாநிலங்களில் , பெட்ரா கர்க்‌ஹாஃப் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , சர்த்தொறிூச் குழு , வடக்கு அமெரிக்கா , பெருநிறுவன தகவல்தொடர்புகள் ,

Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings

Share this article
Share this article
GÖTTINGEN, Germany, July 21, 2021 /PRNewswire/ The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake
1.
In the first six months of the year, we have seen unabated high demand for innovative technologies used in the development and production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines and coronavirus test kits have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various step ....

Puerto Rico , South Korea , Rainer Lehmann , Petra Kirchhoff , Joachim Kreuzburg , Asia Pacific , Watersep Bioseparations , Head Of Corporate Communications Investor Relations , Group Sartorius , Group Lab Products Services Division , Lab Products Services , Lab Products Services Division , Bioprocess Solutions Division , Sartorius Group , Bioprocess Solutions , Executive Board Chairman , Lab Products , Services Division , Middle East , Executive Board , European Summer Time , Corporate Communications , ப்வெர்டோ ரிக்கோ , தெற்கு கொரியா , மழை லெஹ்மன் , பெட்ரா கர்க்‌ஹாஃப் ,

Half-year results of Sartorius Stedim Biotech

Share this article
Share this article
AUBAGNE, France, July 21, 2021 /PRNewswire/ Sartorius Stedim Biotech, a leading partner of the biopharma industry, has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake
1.
In the first six months of the year, we have seen unabated high demand for innovative technologies used in the production of biopharmaceuticals. Orders from customers who manufacture coronavirus vaccines have played an additional important, though not dominant, role in this respect. The acquisitions closed in 2020 also are performing well and have added positive momentum. Our most recent acquisition of a majority stake in CellGenix, a leading global supplier of GMP–grade cell culture components, enables us to provide our customers with even more comprehensive support in moving their drug candidates quickly and efficiently through the various steps of drug ....

Puerto Rico , United States , South Korea , Provence Alpes Côd Azur , Petra Kirchhoff , Joachim Kreuzburg , Asia Pacific , Prnewswire Sartorius Stedim , Watersep Bioseparations , Head Of Corporate Communications Investor Relations , Sartorius Stedim Biotech Group , Danaher Corporation , Stedim Biotech , Middle East , Sartorius Stedim Biotech , European Summer Time , North America , Corporate Communications , ப்வெர்டோ ரிக்கோ , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , பெட்ரா கர்க்‌ஹாஃப் , ஆசியா பெஸிஃபிக் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , ட்யாநேஹர் நிறுவனம் , நடுத்தர கிழக்கு ,

Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) .
Basilea Pharmaceutica AGJuly 14, 2021 GMT
Ad hoc announcement pursuant to Art. 53 LR
Basel, Switzerland, July 14, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union.
Under the terms of the agreement, JSC Lancet is granted the exclusive right to register, distribute and commercialize Zevtera in the license territory, whilst Basilea will supply JSC Lancet with product at a transfer price. In addition, Basilea will receive an upfront payment and be eligible for sales milestone payments. ....

United States , Basel Stadt , Nils Schr , David Veitch , Eurasian Economic Union , Head Of Corporate Communications Investor Relations , Swiss Exchange , Basilea Pharmaceutica Ltd , Eurasian Economic , Chief Executive Officer , Latin America , Middle East , North Africa , Basilea Pharmaceutica , Corporate Communications , ஒன்றுபட்டது மாநிலங்களில் , பேசல் ஸ்ட்யாட்ட் , டேவிட் வைச் , யூரேசியன் பொருளாதார தொழிற்சங்கம் , தலை ஆஃப் பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , சுவிஸ் பரிமாற்றம் , யூரேசியன் பொருளாதார , தலைமை நிர்வாகி அதிகாரி , லத்தீன் அமெரிக்கா , நடுத்தர கிழக்கு , பெருநிறுவன தகவல்தொடர்புகள் ,